Cytovale Inc.

South San Francisco, CA

UEI
TG7HM4HD8594
CAGE
6PS42
Primary NAICS
334516 Analytical Laboratory Instrument Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
2 Tower Pl 18th floor, South San Francisco, CA 94080, USA
Website
cytovale.com
Founded
2013
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 -$311,877
FY2024 $0
FY2023 $599,551

Contract awards

Award Agency Obligated Awarded
Cytovale: the overall objective of this contract is to evaluate the impact of the intellisep test on clinical… 75A50123C00066 Office of the Assistant Secretary for Preparedness and Response $599,551
Patchd, INC R & D for clinical validation of an at-home, deep-learning based, sepsis monitoring system AOI#2… 75A50122C00059 Office of the Assistant Secretary for Preparedness and Response $437,799
Cytovale: advancing a biophysical early sepsis diagnostic towards FDA 510(K) clearance 75A50119C00072 Office of the Assistant Secretary for Preparedness and Response $9,050,674

Grant awards

Award Agency Obligated Awarded
Sbir phase II: a cell analysis platform for low-cost, rapid diagnosis of sepsis using microfluidic technologies 1431033 National Science Foundation $1,419,607
Enabling point of care screening for sepsis using rapid single cell analysis R44HL123878 National Heart Lung and Blood Institute (NIH) $1,484,141
Automated sample preparation for onsite blood-based single- cell assays R43HL123878 National Institutes of Health $225,000
Biomechanical enrichment of malignant cells enabling companion diagnostics R43EB018749 National Institutes of Health $699,986
Robust high-throughput mechanical phenotyping platform for clinical diagnostics R43TR000351 National Institutes of Health $399,719

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Inflammatix, Inc. UEI WK9MLMSHBVL3 Sunnyvale, CA 325413 In-Vitro Diagnostic Substance Manufacturing
Rizlab Health Inc. UEI H75CJVCZZNP3 Princeton, NJ 541330 Engineering Services
Pattern Bioscience, Inc. UEI KGNTWWVCEM33 Austin, TX 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Aptitude Medical Systems Inc. UEI NWWEFYLD9JC3 Goleta, CA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Day Zero Diagnostics Inc. UEI KZKSJLYEAE83 — 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Cytovale Inc. is a San Francisco-based biotechnology company that develops rapid diagnostic tests for life-threatening medical conditions like sepsis. The company provides the federal government with diagnostic devices and technologies, primarily focused on sepsis detection and management.

Cytovale Inc. has received prime federal contract awards from the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). In 2023, ASPR awarded Cytovale a $599,551 firm-fixed-price contract to evaluate the impact of the IntelliSep test on clinical decision-making and sepsis risk stratification through the Solving the Question of Inflammation or Sepsis Hastily - Decision Impact study. Additionally, in 2019, ASPR awarded Cytovale a $9,050,674 cost-sharing contract under the Biomedical Advanced Research and Development Authority's Broad Agency Announcement for advancing Cytovale's biophysical early sepsis diagnostic towards FDA 510(k) clearance. These contracts demonstrate Cytovale's expertise in developing and evaluating sepsis diagnostics for federal agencies.

Cytovale Inc. has also received sub-federal grant funding from Emory University, where it is a sub-awardee under Emory's Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) program. This grant likely supports Cytovale's work in developing point-of-care diagnostic technologies, aligning with the company's focus on rapid sepsis detection.

Quick answers

Is Cytovale Inc. registered in SAM.gov?

Yes. Cytovale Inc.'s SAM.gov registration is active through October 5, 2027.

What is Cytovale Inc.'s CAGE code?

Cytovale Inc.'s CAGE code is 6PS42, and its Unique Entity ID (UEI) is TG7HM4HD8594.

How much has Cytovale Inc. received in federal contracts?

Federal contracts obligated $287,674 to Cytovale Inc. in fiscal years 2023 through 2027.

What is Cytovale Inc.'s most recent federal award?

Cytovale Inc.'s most recent federal contract award is Cytovale: the overall objective of this contract is to evaluate the impact of the intellisep test on clinical… (75A50123C00066), from Office of the Assistant Secretary for Preparedness and Response, on September 19, 2023.

On GovTribe

See Cytovale Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe